Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22097305 | 0.78 | — | — | |
| SCHEMBL6847362 | 0.76 | — | — | |
| SCHEMBL3890503 | 0.75 | TP53 (0.34) | TP53MMP1MMP9MMP12 | |
| SCHEMBL1326408 | 0.75 | TP53 (0.41) | TP53MMP1MMP9MMP12ALDH1A1 | |
| Water SCHEMBL29272691 | 0.72 | TP53 (0.39) | TP53MMP1MMP9MMP12ALDH1A1 | |
| Water SCHEMBL29272692 | 0.72 | TP53 (0.39) | TP53MMP1MMP9MMP12ALDH1A1 | |
| SCHEMBL826030 | 0.70 | — | — | |
| SCHEMBL10791737 | 0.70 | — | — | |
| SCHEMBL29033107 | 0.70 | ALDH1A1 (0.39) | TP53MMP1MMP9MMP12ALDH1A1 | |
| SCHEMBL3128596 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11411251-B2 | Electrolyte, lithium secondary battery including the electrolyte, and method of manufacturing the electrolyte | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-08-09 | — | — | US | claimed |
| EP-3667773-A1 | ELECTROLYTE, LITHIUM SECONDARY BATTERY INCLUDING THE ELECTROLYTE, AND METHOD OF MANUFACTURING THE ELECTROLYTE | Samsung SDI Co., Ltd. (KR) | 2020-06-17 | — | — | EP | claimed |
| CN-111293360-A | Electrolyte and lithium secondary battery comprising the same | 三星电子株式会社 | 2020-06-16 | — | — | CN | claimed |
| US-20200185775-A1 | ELECTROLYTE, LITHIUM SECONDARY BATTERY INCLUDING THE ELECTROLYTE, AND METHOD OF MANUFACTURING THE ELECTROLYTE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-06-11 | — | — | US | claimed |
| US-11411251-B2 | Electrolyte, lithium secondary battery including the electrolyte, and method of manufacturing the electrolyte | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-08-09 | — | — | US | disclosed |
| EP-3667773-A1 | ELECTROLYTE, LITHIUM SECONDARY BATTERY INCLUDING THE ELECTROLYTE, AND METHOD OF MANUFACTURING THE ELECTROLYTE | Samsung SDI Co., Ltd. (KR) | 2020-06-17 | — | — | EP | disclosed |
| CN-111293360-A | Electrolyte and lithium secondary battery comprising the same | 三星电子株式会社 | 2020-06-16 | — | — | CN | disclosed |
| US-20200185775-A1 | ELECTROLYTE, LITHIUM SECONDARY BATTERY INCLUDING THE ELECTROLYTE, AND METHOD OF MANUFACTURING THE ELECTROLYTE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-06-11 | — | — | US | disclosed |
| US-20200185775-A1 | ELECTROLYTE, LITHIUM SECONDARY BATTERY INCLUDING THE ELECTROLYTE, AND METHOD OF MANUFACTURING THE ELECTROLYTE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-06-11 | — | — | US | disclosed |
| US-9242974-B2 | Processes for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140073797-A1 | PROCESSES FOR THE PREPARATION OF 2-FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8552162-B2 | Processes for the preparation of 2 fluoro 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20040171818-A1 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| EP-1265909-A2 | PROCESS FOR THE PREPARATION OF 6-O-PROPARGYL ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1257531-A2 | METHOD FOR THE PREPARATION OF CARBOTHIOIC ACIDS | Abbott Laboratories (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020133032-A1 | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods | ABBOTT LABORATORIES | 2002-09-19 | — | — | US | disclosed |
| US-20020091107-A1 | Oxazolidinone antibacterial agents | ABBOTT LABORATORIES | 2002-07-11 | — | — | US | disclosed |
| WO-2002020515-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2001077134-A2 | PROCESS FOR THE PREPARATION OF 6-O-PROPARGYL ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001062722-A2 | METHOD FOR THE PREPARATION OF FLUTICASONE AND RELATED 17BETA-CARBOTHIOIC ESTERS USING A NOVEL CARBOTHIOIC ACID SYNTHESIS AND NOVEL PURIFICATION METHODS | ABBOTT LABORATORIES (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200185775-A1 | ELECTROLYTE, LITHIUM SECONDARY BATTERY INCLUDING THE ELECTROLYTE, AND METHOD OF MANUFACTURING THE ELECTROLYTE | RER1, CLCN2, NHERF1 | TP53 1827/4885MMP1 2208/4885MMP9 700/4885 |
| US-20020133032-A1 | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods | HSD17B7, CYP17A1, NR5A1 | TP53 3419/4885MMP1 1346/4885MMP9 2896/4885 |
| US-11411251-B2 | Electrolyte, lithium secondary battery including the electrolyte, and method of manufacturing the electrolyte | RER1, CLCN2, NHERF1 | TP53 1827/4885MMP1 2208/4885MMP9 700/4885 |
| US-20040171818-A1 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | CYP2B6, CYP7A1, CYP2D6 | TP53 4882/4885MMP1 3029/4885MMP9 2168/4885 |
| US-20140073797-A1 | PROCESSES FOR THE PREPARATION OF 2-FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | CYP2F1, CYP2B6, CYP4F11 | TP53 4872/4885MMP1 2908/4885MMP9 3735/4885 |
| US-20020091107-A1 | Oxazolidinone antibacterial agents | OXA1L, TOP1, MT-ND1 | TP53 3958/4885MMP1 1191/4885MMP9 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.